Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy

Andreea Parosanu 1, Ioana Miruna Stanciu 2, Cristina Pirlog 1, Cristina Orlov Slavu 1, Horia Cotan 1, Cristian Iaciu 1, Ana Maria Popa 1, Mihaela Olaru 1, Oana Moldoveanu 2, Baston Catalin 2, Cornelia Nitipir 1

1. Oncology, Elias Emergency University Hospital, Bucharest, ROU 2. Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU 3. Urology, Funderi Clinical Institute, Bucharest, ROU

Corresponding author: Ioana Miruna Stanciu, ioanamiruna95@yahoo.com

Abstract

With recent advances in oncology, immune checkpoint inhibitors (ICIs) have become a milestone in immuno-oncology. Unfortunately, although ICIs have demonstrated improved clinical efficacy in a broad spectrum of cancers, many patients do not respond to this newer therapy. As a result, it is crucial to identify predictive factors of response to immunotherapy in patients with kidney cancer. This review discusses the research investigating potential biomarkers of response to ICIs in renal cell carcinoma.

Introduction And Background

Renal cell carcinoma (RCC) is the most common type of renal malignancy, contributing 2.2% of the total number of new cancer cases diagnosed in 2020 [1]. Even though clinical staging is essential to help plan initial treatment, many other factors can predict survival and guide treatment options. They represent valuable tools for a successful outcome in individual treatment. While surgery remains an essential curative treatment option for stages I-III RCC, systemic therapy is the first option for stage IV [2].

The treatment of advanced kidney cancer has evolved dramatically over the past 40 years. In the 1980s, interferon was the only effective therapeutic option for locally advanced or metastatic RCC. The paradigm for treating stage IV RCC has changed over the years with the introduction of tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs) [3]. With so many therapies available to treat advanced kidney cancer and many more in development, it is essential to find prognostic factors for personalized oncological treatment.

This review aims to answer the following questions: are the standard prognostic models still relevant in the era of immune checkpoint therapy? And which patients will benefit the most from immunotherapy?

Review

We reviewed the PubMed database from January 2018 to August 2022 to identify relevant studies evaluating prognostic models for patients with renal cell carcinoma treated with immunotherapy. The established inclusion criteria included only English-language research articles that explored the development or validation of prognostic biomarkers of response to modern immunotherapy in advanced and metastatic renal cell carcinoma. From the 97 results found, 38 studies met our criteria.

Improving risk stratification models

In the early 1990s, Motzer et al. developed the Memorial Sloan-Kettering Cancer Centre (MSKCC) prognostic model for patients with metastatic kidney cancer treated as initial systemic therapy with cytokine interleukin two (IL2) or interferon-alpha (IFN-α). This risk model has been proposed and validated to predict survival based on five pretreatment features: low-performance status, time from diagnosis to treatment interval of less than one year, anemia, elevated lactate dehydrogenase, and corrected serum calcium levels. In addition, patients were categorized according to the number of risk factors into three categories: favorable, intermediate, and poor [4]. Lately, in the era of vascular endothelial growth factor (VEGF) targeted therapy was developed the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. This score was designed by adding two new variables (platelet and neutrophil count) to the MSKKC score [5].

When these two scores were proposed, cytokines and anti-VEGF targeted agents were the standard of care for metastatic renal cell carcinoma. However, since 2015 immune checkpoint inhibitors have changed the treatment paradigm in advanced kidney cancer. So are the previous prognostic models still accurate?
Immune checkpoint pivot trials only evaluated the IMDC risk status [6]. Thus, we must reevaluate these models and identify new risk factors that make patients with advanced or metastatic kidney cancer more likely to respond to immunotherapy.

Sagie et al. recently proposed an updated risk stratification model in patients with metastatic kidney cancer treated with checkpoint inhibitors. They demonstrated that in addition to the previous IMDC risk factors, the presence of liver metastasis and the absence of the surgical removal of the primary tumor are negative predictive markers [7]. Several studies have also explored the relationship between sites of metastases and prognosis in RCC patients [8,9]. Moreover, Interno et al. suggested that PD-1 is poorly expressed in brain metastases and immune checkpoint inhibitors seemed less effective in these patients [10].

For early-stage RCC, surgery remains the mainstay of curative therapy. However, advanced RCC needs both local and systemic treatments. Complete cytoreductive surgery in RCC has been associated with better outcomes in patients with good performance status, clear cell subtype histology, and without cerebral metastasis. The goal of surgical treatment was to reduce tumor burden and to achieve negative surgical margins in order to improve response to ICIs and survival [11].

**The role of PD-L1 as a predictive or prognostic marker**

Up to 30% of RCC overexpressed PD-L1 [12]. Higher expression of PD-L1 was associated with adverse clinicopathological features: poorly differentiated cells, necrosis, and sarcomatoid differentiation [13]. In some malignancies, the tumor PD-L1 expression can predict the response to anti-PD-1/PD-L1 therapy. Thus, in metastatic RCC, the role of PD-L1 as a predictive or prognostic marker is unclear. We reviewed the ICIs in first-line renal cancer trials to evaluate if PD-L1 expression matters (Table 1).

| Author                  | Trial          | Subgroup                  | 12-month OSR | Median PFS |
|-------------------------|----------------|---------------------------|--------------|------------|
| Rini et al., 2019       | KEYNOTE-426    | PD-L +                    | 90.1%        | 15.3 months |
|                         |                | PD-L -                    | 91.5%        | 15.0 months |
|                         |                | Sarcomatoid features      | 83.4%        | median not reached |
| Choueiri et al., 2020   | JAVELIN Renal 101 | PD-L +                  | 55.2%        | 13.8 months |
|                         |                | Overall population        | 51.7%        | 13.8 months |
|                         |                | Sarcomatoid features      | 46.8%        | 7 months |
| Motzer et al., 2018     | CheckMate 214  | PD-L +                    | 69%          | 22 months |
|                         |                | PD-L -                    | 54%          | 11 months |
|                         |                | Sarcomatoid features      | 56.7%        | 8.4 months |
| Rini et al., 2019       | IMmotion 151   | OS                        | 34 months    | 11.2 months |
|                         |                | Atezolizumab + Bevacizumab | 32.7 months  | 7.7 months |
CheckMate 025 was the first study to evaluate the use of PD-L1 expression as a biomarker of response to immunotherapy in advanced kidney cancer. This trial reported that nivolumab improved overall survival (OS) compared to everolimus regardless of PD-L1 expression (21.9 months versus 18.8 months in the PD-L1 positive arm, and 26.8 months versus 20.3 months in the PD-L1 negative arm). However, a positive PD-L1 expression was associated with an unfavorable prognosis because all patients who expressed PD-L1 more than 1% had worse outcomes in both treatment lines [18].

Furthermore, ICIs plus tyrosine kinase inhibitors (TKIs) were tested in three phase III trials, including KEYNOTE-426, JAVELIN Renal 101, and CheckMate 9ER. These studies confirmed increased overall survival rates (OSR) in the ICI+TKI arm irrespective of PD-L1 status [14,15,19].

On the contrary, the CheckMate 214 trial, a phase III study of nivolumab and ipilimumab versus sunitinib, has shown remarkable overall response rates of first-line immunotherapy-based combination in patients expressing PD-L1 over 1% (69% versus 24%) [16].

The combinations of ICIs with angiogenesis inhibitors have demonstrated similar results. For example, in the IMmotion151 trial, atezolizumab combined with bevacizumab (an anti-VEGF monoclonal antibody) showed improved clinical outcomes compared with sunitinib in the PD-L1-positive population. The progression-free survival (PFS) was 11.2 months in the atezolizumab plus bevacizumab versus 7.7 months in the sunitinib arm [17].

Post-hoc analyses of pivotal clinical trials for first-line metastatic kidney cancer included immunotherapy efficacy in tumors with sarcomatoid features. About 5-20% of advanced kidney cancers harbor sarcomatoid differentiation, the most clinically aggressive phenotype. Current studies have shown that RCC with sarcomatoid features may express even higher levels of PD-L1. Therefore, ICIs can be considered a potential therapeutic option [20]. Exploratory analysis of the abovementioned trials confirmed the efficacy of ICIs among patients with sarcomatoid histology. For example, updated findings from the CheckMate 214 trial demonstrated the promising efficacy of nivolumab plus ipilimumab compared to sunitinib (ORR 56.7% versus 19%) in RCC with sarcomatoid features [21]. In addition, in the subgroup of patients with sarcomatoid features from the CheckMate 9ER trial, the combination of nivolumab plus cabozantinib doubled PFS compared to sunitinib (10.3 months versus 4.2 months) [19].

Recent data reported that the prognostic significance of PD-L1 expression is not restricted to clear cell histology [22]. In addition, some studies showed higher levels of PD-L1 in non-clear cell RCC histological subtypes (papillary or chromophobe) than in clear cell RCC [23,24]. It has already been established that non-clear cell RCCs have a more aggressive clinical course. Moreover, in these tumors, PD-L1 positivity was significantly associated with adverse tumor features such as higher TNM stage and Fuhrman grade and reduced overall survival [25].
Other distinctive renal cell carcinoma histological features are inherited forms of kidney cancer. For example, the mutation in the fumarate hydratase gene is associated with hereditary leiomyomatosis and renal cell carcinomas [26]. In addition, despite the currently limited data, PD-L1 positive expression in patients with this hereditary syndrome was associated with higher pathological TNM stages, higher tumor grades, and increased cancer-specific mortality. However, despite the aggressive tumor characteristics, these PD-L1-positive tumors may benefit from anti-PD-1 therapy [27].

So, is PD-L1 expression assessment required for RCC treatment? Currently, the PD-L1 status is poorly understood and does not play a role in choosing immunotherapy. Further follow-up of these trials is needed to confirm the advantages mentioned above.

Other potential biomarkers

Because kidney cancers are highly immunogenic and vascularized tumors, immunotherapy has shown great potential in using tumor-infiltrating immune cells as promising biomarkers of response to therapy. Several studies have illustrated the robust association between tumor immune microenvironment and the response to immunotherapy. Therefore, many researchers collected data from The Cancer Genome Atlas (TCGA) database and developed a range of immunogenomic landscape signatures to predict immunotherapy response. These immuno-scores, including TMB (tumor mutational burden), PD-L1, CTLA4, or immune-related genes (HLA-B, HLA-A, HLA-DRA), expand knowledge in tumor immune status and provide a potent prediction tool for the future [28,29].

With the approval of ICI blockade in metastatic RCC, is there a biomarker for CTLA-4? There is strong evidence that the DNA methylation of the gene encoding for the CTLA4 protein predicts response to anti-PD-1 and anti-CTLA-4 in patients with melanoma and RCC. CTLA4 methylation status can be quantified using immunohistochemistry and methylation-specific PCR. Klümper et al.’s findings suggest that the CTLA4 hypomethylation status may predict favorable outcomes in RCC patients treated with immunotherapy [30].

There is a strong relationship between inflammation and cancer. Chronic inflammation promotes immune evasion and creates a microenvironment that sustains angiogenesis, tumor initiation, survival, and proliferation. On the other hand, tumor-associated inflammation can lead to aberrant epigenetic alterations that also contribute to the promotion of its growth and survival [31]. RCC is a pro-angiogenic tumor type, as demonstrated by the efficacy of anti-angiogenic agents. RCC is also considered a highly immunogenic tumor. Immunotherapeutic strategies showed efficient activity, including high-dose interleukin-2 or interferon-alpha and, more recently, immune checkpoint inhibitors [32].

There are several inflammation-related plasma biomarkers, such as prognostic nutritional index (PNI), eosinophils levels, lymphocyte-platelet ratio (PLR), and lymphocyte-neutrophil ratio (NLR), which can be affordable and readily available biomarkers of the response to immunotherapy in patients with kidney cancer. NLR and PLR represent a balance between tumor inflammation and immune status. Therefore, an increased NLR is associated with a lower probability of achieving an adequate anti-tumor immune response [33,34]. A meta-analysis including patients with metastatic RCC treated with ICIs suggested that elevated NLR and PLR were associated with unsuccessful treatment outcomes. However, a lower NLR following treatment with ICIs indicated better overall survival [35]. On the other hand, Herrmann et al. demonstrated that elevated blood eosinophil levels within the first six weeks of therapy were associated with improved PFS and OS in patients with RCC treated with nivolumab. This study shows that the blood eosinophil count was not an inflammation response but an allergic response [36].

Another important prognostic factor is the patient’s immune–nutritional status. Several studies reported an association between body mass index (BMI), prognostic nutritional index (PNI), and the response to immunotherapy. [37,38]. PNI is calculated using albumin and lymphocyte counts and reflects the relationship between nutritional status and systemic inflammation. There is a vicious cycle between nutrition and inflammation. Hypoalbuminemia may lead to cachexia and impaired immune function [39]. For example, Peng et al. showed that low PNI was an independent poor prognostic factor for response to ICIs in RCC [40].

Moreover, there is an established link between obesity, inflammation, and cancer. Obesity may cause one-quarter of cancer deaths. Obesity also predisposes to inflammation and impacts the response to immunotherapy by activating pro-inflammatory mediators such as interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF α) [41]. Aurilio et al. have investigated the obesity paradox for cancer immunotherapy. Their findings demonstrated that even if obesity increased the risk of kidney cancer, patients with RCC and high body mass index (BMI over 25 kg/m2) responded better to immunotherapy with TRU+ICI [42]. However, research in this field is just emerging, and further research needs to be done to fully understand how obesity modulates the immune system and influences the efficacy of immunotherapy.

Conclusions

The prognosis of advanced RCC was primarily based on pathological staging, histological type, grade, and
patient performance status. Today, we use risk stratification models to evaluate prognosis and improve treatment. Thus, based on the data available, there are no established predictive biomarkers to distinguish patients most likely to respond to ICIs in RCC. We look forward to more successful research on the obesity paradox, and to further developing potential biomarkers, such as molecular signatures, to maximize the benefit of patients from ICIs.

**Additional Information**

**Disclosures**

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Global Cancer Observatory. Kidney fact sheet. (2022). Accessed: 25 September 2022: https://gco.iarc.fr/today/data-factsheets/cancers/29-Kidney-fact-sheet.pdf.

2. National Comprehensive Cancer Network. Guidelines. (2022). Accessed: 25 September 2022: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.

3. Hizal M, Sendur MA, Bilgin B, Akinci MB, Sener Dede D, Yalcin B: A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint. Curr Med Res Opin. 2020, 36:625-35. 10.1080/03007995.2020.1716705

4. Motzer RJ, Mazumdar M, Baccil J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999, 17:2350-40. 10.1200/JCO.1999.17.8.2350

5. Pérez-Valderrama B, Arranz Arija JA, Rodriguez Sánchez A, et al.: Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Germitourinary Group (SOGUG) SPAZO study. Ann Oncol. 2016, 27:706-11. 10.1093/annonc/mdv601

6. Lopez-Beltran A, Henriquez V, Cimadore A, et al.: The identification of immunomarkers in kidney cancers. Front Oncol. 2018, 8:456. 10.3389/fonc.2018.00456

7. Sabir S, Safarzy M, Levartovsky M, Gantz Sorotsky H, Berger R, Perrick R, Gadot M: RCC real-world data: prognostic factors and risk stratification in the immunotherapy era. Cancers (Basel), 2022, 14:5127. 10.3390/cancers14133127

8. Mollica V, Rizzo A, Tassinari E, et al.: Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. Anticancer Drugs. 2021, 32:74-81. 10.1097/CAD.0000000000001017

9. Botticelli A, Cirillo A, Scagnoli S, et al.: The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy. Vaccines (Basel). 2020, 8:203. 10.3390/vaccines8020203

10. Interno V, De Santis P, Stucci LS, Ruda R, Tucci M, Soffietti R, Porta C: Prognostic factors and current treatment strategies for renal cell carcinoma metastatic to the brain: an overview. Cancers (Basel). 2021, 13:2114. 10.3390/cancers13092114

11. Khochikar MV: Cytoreductive surgery in the management of renal tumours: rationale, current evidence and future perspectives. Indian J Surg Oncol. 2017, 8:33-8. 10.1097/IJSO.0000000000000192

12. Callea M, Albige G, Gupta M, et al.: PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. Cancer Immunol Res. 2015, 3:1158-64. 10.1158/2326-6066.CIR-15-0045

13. Wang Y, Xeng F, Kong L, Yu J: PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016, 9:5023-39. 10.2147/OTT.S105862

14. Rini BI, Plimack ER, Stus V, et al.: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019, 380:1116-27. 10.1056/NEJMoa1816714

15. Choueiri TK, Motzer RJ, Rini BI, et al.: Updated efficacy results from the JAVELIN Renal 101 trial: first-line axelvumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020, 31:1050-9. 10.1093/annonc/mdaa0010

16. Motzer RJ, Tannir NM, McDermott DF, et al.: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018, 378:1277-90. 10.1056/NEJMoa1712126

17. Rini BI, Polwes T, Atkins MB, et al.: Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019, 393:2404-15. 10.1016/S0140-6736(19)31275-8

18. Motzer RJ, Escudier B, McDermott DF, et al.: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015, 373:1805-15. 10.1056/NEJMoa1510665

19. Choueiri TK, Powles T, Buroto M, et al.: Nivolumab plus cabozantinib versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2021, 384:829-41. 10.1056/NEJMoa2026982

20. Blum KA, Gupta S, Tickoo SK, et al.: Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020, 17:659-78. 10.1038/s41571-020-00382-9

21. Tannir NM, Signoretti S, Choueiri TK, et al.: Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2021, 27:78-86. 10.1158/1078-0432.CCR-20-2065

22. Walter B, Gil S, Naihinch X, Kuhlak MJ, Linelhan WM, Sinivasan R, Merino MJ: Determination of the
expression of PD-L1 in the morphologic spectrum of renal cell carcinoma. J Cancer. 2020, 11:5596-603. 10.7155/jca.55738

23. Choueiri TK, Fay AP, Gray KP, et al.: PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014, 25:2178-84. 10.1093/annonc/mdu445

24. Shen M, Chen G, Xie Q, Li X, Xu H, Wang H, Zhao S: Association between PD-L1 expression and the prognosis and clinicopathologic features of renal cell carcinoma: a systematic review and meta-analysis. Urol Int. 2020, 104:533-41. 10.1159/000506296

25. Iacovelli R, Nolè F, Verri E, et al.: Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol. 2016, 11:143-8. 10.1007/s11523-015-0392-7

26. Gleeson JP, Nikolovski I, Dinatelle R, et al.: Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma. Clin Cancer Res. 2021, 27:2919-9. 10.1158/1078-0432.CCR-20-4567

27. Alaghebandan R, Stethlik I, Trpkov K, et al.: Programmed death-1 (PD-1) receptor/ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. Ann Diagn Pathol. 2017, 29:17-22. 10.1016/j.anndiagpath.2017.04.007

28. Tao H, Li Z, Mei Y, Li X, Lou H, Dong L, Zhou L: Integrative bioinformatics analysis of a prognostic index and immunotherapeutic targets in renal cell carcinoma. Int Immunopharmacol. 2020, 87:106852. 10.1016/j.intimp.2020.106852

29. Xie Z, Wu L, Hua S, et al.: External validation of the prognostic value of an immune-associated gene panel for clear cell renal cell carcinomas. Front Cell Dev Biol. 2021, 9:794840. 10.3389/fcell.2021.794840

30. Klümper N, Ralser DJ, Zarbl R, et al.: CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. J Immunother Cancer. 2021, 9:10.1156/jtcc-2021-002949

31. Greten FR, Grivennikov SI: Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019, 51:27-41. 10.1016/j.immuni.2019.06.025

32. Shi J, Wang K, Xiong Z, et al.: Impact of inflammation and immunotherapy in renal cell carcinoma. Oncol Lett. 2020, 20:272. 10.3892/ol.2020.12135

33. Patel A, Ravaud A, Motzer RJ, et al.: Neutrophil-to-lymphocyte ratio as a prognostic factor of disease-free survival in postnephrectomy high-risk locoregional renal cell carcinoma: analysis of the S-TRAC trial. Clin Cancer Res. 2020, 26:4865-8. 10.1158/1078-0432.CCR-20-0704

34. Shao Y, Wu B, Jia W, Zhang Z, Chen Q, Wang D: Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. BMC Urol. 2020, 20:90. 10.1186/s12894-020-00665-8

35. Wang X, Su S, Guo Y: The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2017, 8:84506-14. 10.18632/oncotarget.21108

36. Herrmann T, Ginzac A, Molnar I, Bailly S, Durando X, Mahammedi H: Neutrophil-to-lymphocyte ratio as a prognostic factor of disease-free survival in postnephrectomy high-risk locoregional renal cell carcinoma: a retrospective study. Cancer Med. 2021, 10:6705-13. 10.1002/cam4.4208

37. Ni L, Huang J, Ding J, et al.: Prognostic Nutritional Index Predicts response and prognosis in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Nutr. 2022, 9:823087. 10.3389/fnut.2022.823087

38. Yasar HA, Bir Yucel K, Arslan C, et al.: The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer. J Oncol Pharm Pract. 2020, 26:1110-6. 10.1177/1078155219883004

39. Johannet P, Sawyers A, Qian Y, et al.: Baseline prognostic nutritional index changes and pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. J Immunother Cancer. 2020, 8:16.1156/jtcc-2020-001674

40. Peng Q, Liu L, Li T, Lei C, Wang H: Prognostic impact of prognostic nutritional index on renal cell carcinoma: A meta-analysis of 7,629 patients. PLoS One. 2022, 17:e0265119. 10.1371/journal.pone.0265119

41. Assumpção JA, Pasquarelli-do-Nascimento G, Duarte MS, Bonamino MH, Magalhães KG: The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy. J Biomed Sci. 2022, 29:12. 10.1186/s12972-022-00796-0

42. Aurillo G, Piva F, Santoni M, et al.: The role of obesity in renal cell carcinoma patients: clinical-pathological implications. Int J Mol Sci. 2019, 20:3683. 10.3390/ijms20223683